Works matching IS 1473-7167 AND VI 24 AND IP 2 AND DT 2024

Results: 15

Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 217, doi. 10.1080/14737167.2023.2291155

By:

Cher, Boon Piang;
Goh, Sharon;
Aziz, Mohamed Ismail Abdul;
Wong, Grace;
Ng Chee Hui, Raymond;
Ong, Benjamin Shao-Kiat;
Ng, Kwong-Hoe

Publication type:

Article

Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 285, doi. 10.1080/14737167.2023.2270159

By:

Kang, Shuo;
Wang, Xiaohui;
Pan, Zhenhua;
Liu, Huanlong

Publication type:

Article

A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 227, doi. 10.1080/14737167.2023.2297790

By:

Macía, Manuel;
Díaz-Encarnación, Montserrat;
Solans-Laqué, Roser;
Mallol, Elisenda Pomares;
Castells, Alejandra García;
Escribano, Cristina;
de Arellano, Antonio Ramírez

Publication type:

Article

Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 203, doi. 10.1080/14737167.2023.2296562

By:

Gloria, Mac Ardy Junio;
Thavorncharoensap, Montarat;
Chaikledkaew, Usa;
Youngkong, Sitaporn;
Thakkinstian, Ammarin;
Chaiyakunapruk, Nathorn;
Ochalek, Jessica;
Culyer, Anthony J.

Publication type:

Article

The role of insurance policies in the drug pricing landscape.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 189, doi. 10.1080/14737167.2023.2292693

By:

Savova, Alexandra;
Manova, Manoela;
Tachkov, Konstantin;
Petrova, Guenka

Publication type:

Article

Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 237, doi. 10.1080/14737167.2023.2297926

By:

Mestre-Ferrandiz, Jorge;
Czech, Marcin;
Smolen, Josef S.;
Cornes, Paul;
Aapro, Matti S.;
Danese, Silvio;
Deitch, Stephen;
Tyldsley, Hannah;
Foster, Will;
Shah, Pooja;
Latymer, Mark;
Vulto, Arnold G.

Publication type:

Article

Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program.

Published in:

2024

By:

DiStefano, Michael J.;
Zemplenyi, Antal;
Anderson, Kelly E.;
Mendola, Nicholas D.;
Nair, Kavita V.;
McQueen, Robert Brett

Publication type:

Report

Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country.

Published in:

2024

By:

Abdullah, Saad;
Saleem, Zikria;
Godman, Brian

Publication type:

Editorial

Developing the Lebanese health economic evaluation guideline.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 315, doi. 10.1080/14737167.2023.2280213

By:

Daccache, Caroline;
Karam, Rita;
Evers, Silvia M.A.A.;
Hiligsmann, Mickaël;
Rizk, Rana

Publication type:

Article

Payer and Developer perspectives on alternative payment models.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 293, doi. 10.1080/14737167.2023.2276374

By:

Moradian, Renita;
Meshesha, Tsega;
Trusheim, Mark;
Barlow, Jane F

Publication type:

Article

Social care data in the UK; current landscape, challenges, and future recommendations.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 303, doi. 10.1080/14737167.2023.2274843

By:

Mendes, Diana;
Wood, Robert;
Seif, Monica;
Collings, Shuk-Li

Publication type:

Article

Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 181, doi. 10.1080/14737167.2023.2282680

By:

Kaló, Zoltán;
Niewada, Maciej;
Bereczky, Tamás;
Goettsch, Wim;
Vreman, Rick A;
Xoxi, Entela;
Trusheim, Mark;
Callenbach, Marcelien H E;
Nagy, László;
Simoens, Steven

Publication type:

Article

Canadian English translation and linguistic validation of the 13-MD to measure global health-related quality of life.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 267, doi. 10.1080/14737167.2023.2268275

By:

Poder, Thomas G.;
Touré, Moustapha

Publication type:

Article

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 251, doi. 10.1080/14737167.2023.2263166

By:

Wolters, Sharon;
de Jong, Lisa A;
Jansen, Christel;
Jansman, Frank GA;
Postma, Maarten J

Publication type:

Article

Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 273, doi. 10.1080/14737167.2023.2263164

By:

Bashari, Negin;
Safaei Lari, Majid;
Darvishi, Ali;
Daroudi, Rajabali

Publication type:

Article